Page last updated: 2024-11-12

urb 524

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10108554
CHEMBL ID431202
SCHEMBL ID530169
MeSH IDM0454123

Synonyms (17)

Synonym
CHEMBL431202 ,
(3-phenylphenyl) n-cyclohexylcarbamate
cyclohexyl-carbamic acid biphenyl-3-yl ester
urb524
bdbm50128585
biphenyl-3-yl cyclohexylcarbamate
cyclohexylcarbamic acidbiphenyl-3-yl ester
A7927
AKOS015909861
SCHEMBL530169
[1,1'-biphenyl]-3-yl cyclohexylcarbamate
biphenyl-3-yl-cyclohexylcarbamate
546141-07-5
n-cyclohexylcarbamic acid [1,1'-biphenyl]-3-yl ester
biphenyl-n-cyclopentyl-carbamate
PD184768
[1,1'-biphenyl]-3-ylcyclohexylcarbamate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Homo sapiens (human)IC50 (µMol)0.06300.00020.59827.0000AID346666; AID612783
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)0.06310.00051.33138.0000AID1799925; AID242504; AID618766; AID71599
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
fatty acid catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionFatty-acid amide hydrolase 1Homo sapiens (human)
monoacylglycerol catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
phospholipid bindingFatty-acid amide hydrolase 1Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 1Homo sapiens (human)
identical protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
acylglycerol lipase activityFatty-acid amide hydrolase 1Homo sapiens (human)
amidase activityFatty-acid amide hydrolase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneFatty-acid amide hydrolase 1Homo sapiens (human)
cytoskeletonFatty-acid amide hydrolase 1Homo sapiens (human)
organelle membraneFatty-acid amide hydrolase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID618764Metabolic stability of the compound in Wistar rat plasma assessed as half life at 1 uM by RP-HPLC analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID618825Chemical stability of the compound in 0.01 M borate buffer assessed as half life at 1 uM and pH 9.0 by HPLC analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID618762Chemical stability of the compound in 0.01 M PBS assessed as compound remaining at pH 7.0 by HPLC analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID618826Chemical stability of the compound in 0.01 M borate buffer assessed as half life at 300 nM and pH 9.0 by HPLC analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID71470Fatty acid amide hydrolase inhibitory activity in rat brain membrane using [3H]anandamide as a substrate2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors.
AID1363878Inhibition of FAAH in Wistar rat brain membranes using [3H]-anandamide as substrate preincubated for 10 mins followed by substrate addition measured after 4 mins by liquid scintillation counting method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
AID618827Chemical stability of the compound in 0.01 M borate buffer assessed as half life at 100 nM and pH 9.0 by HPLC analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID404765Inhibition of FAAH in rat brain membrane assessed as [3H]anandamide hydrolysis2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates.
AID618829Hydrolytic rate constant, log k of the compound in Wistar rat liver S9 fraction2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID618828Hydrolytic rate constant, log k of the compound in Wistar rat plasma2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID618763Chemical stability of the compound in 0.01 M borate buffer assessed as half life at pH 9.0 by HPLC analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID618830In vivo displacement of [3H]-anandamide from rat brain FAAH after 30 mins by scintillation counting2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID612783Inhibition of FAAH2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).
AID1441168Displacement of [3H]anandamide from FAAH in rat brain membranes after 30 mins by liquid scintillation counting2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolas
AID618765Metabolic stability of the compound in Wistar rat liver S9 fraction assessed as half life at 1 uM by RP-HPLC analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID71599Inhibition of [3H]anandamide binding to fatty acid amide hydrolase of rat brain membrane2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors.
AID346666Inhibition of human FAAH2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
AID618766Displacement of [3H]-anandamide from rat brain FAAH after 30 mins by scintillation counting2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.
AID242504Inhibition of [3H]anandamide binding to fatty acid amide hydrolase of rat brain membranes2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.
AID1799925FAAH Inhibition Assay from Article 10.1002/cmdc.200500017: \\Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring.\\2006ChemMedChem, Jan, Volume: 1, Issue:1
Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (55.56)29.6817
2010's4 (44.44)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.15 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]